Eloxx Pharmaceuticals, Inc. — 10-Q Summary
Reporting period: Three and nine months ended September 30, 2022. Filed November 10, 2022. Eloxx is a clinical-stage biopharmaceutical company developing ribosome-modulating therapies for rare diseases and cancers. It has no approved products and has generated no product revenue.
Financial performance and position
| Metric | Q3 2022 | Q3 2021 | Nine months 2022 | Nine months 2021 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Research and development | $4.9 million | $5.2 million | $20.4 million | $15.0 million |
| General and administrative | $2.3 million | $5.0 million | $8.0 million | $16.7 million |
| Net loss | $7.5 million | $9.9 million | $29.7 million | $54.6 million |
| Net loss per share | $0.09 | $0.11 | $0.34 | $0.85 |
- Cash and liquidity: At September 30, cash and cash equivalents were $24.6 million, plus $0.3 million restricted cash. Current assets were $25.7 million and current liabilities $21.7 million, for working capital of approximately $4.0 million.
- Cash flow: Nine-month operating cash use was $26.2 million, compared with $25.1 million in 2021. Investing cash use was $0.1 million; financing provided $8.5 million, all from collaboration-partner advances. Cash, cash equivalents and restricted cash fell $17.8 million from year-end 2021.
- Debt: Hercules term-loan principal outstanding was $12.5 million; carrying value, net of discount, was $11.6 million. The interest rate was 12.5% at quarter-end. Principal amortization is scheduled to begin April 2023, subject to possible milestone-based extension. A $10.0 million minimum qualified-cash covenant applied; the company reported covenant compliance at September 30.
- Other balance-sheet items: Advances from collaboration partners were $12.2 million, total liabilities $31.9 million, and stockholders’ equity was negative $5.0 million. Profit margins are not meaningful because the company has no revenue.
Changes versus the prior comparable period
- Q3 net loss narrowed by $2.4 million year over year; nine-month net loss narrowed by $24.9 million. The nine-month comparison is substantially affected by $22.7 million of acquired in-process R&D expense recorded in 2021 for the Zikani acquisition, with no comparable 2022 charge.
- Nine-month R&D expense rose $5.4 million, primarily reflecting preclinical work on inhaled ELX-02 and other development costs. Nine-month G&A fell $8.8 million, largely due to lower personnel costs and stock-based compensation.
- Cash used in operations remained broadly similar year over year, while financing cash inflow fell from $50.9 million in the first nine months of 2021 to $8.5 million in 2022; 2021 included public-offering proceeds and debt financing.
Outlook, developments and risks
- Going concern and funding: Management said September 30 cash would not fund current and planned operations for the next 12 months after filing and that substantial additional funding would be needed by the end of the first half of 2023. The filing states that recurring losses and funding uncertainty raise substantial doubt about the company’s ability to continue as a going concern. If financing is unavailable, it may reduce or defer spending or curtail development.
- Pipeline: The company stopped subcutaneous ELX-02 development for cystic fibrosis after the Phase 2 combination trial with ivacaftor missed secondary efficacy endpoints. The Cystic Fibrosis Foundation (CFF) ended further funding for that program; $7.4 million of the amended award became unavailable. The company planned inhaled ELX-02 work, dependent on new funding. It reported that the Alport syndrome Phase 2 trial began in November 2022, with results expected in the first half of 2023. ZKN-013 was in IND-enabling development, with an IND filing targeted for late 2022 or early 2023.
- Collaboration funding: The CFF had paid $8.5 million under its 2022 award by September 30. The filing also reported $2.4 million in potential CFF funding under another award, of which $0.3 million was received after quarter-end.
- Debt and listing risks: The Hercules lender may accelerate repayment after an uncured covenant breach. The company also faced Nasdaq minimum-bid-price and minimum-market-value compliance deadlines and was seeking approval for a possible reverse split of 1-for-2 to 1-for-40.
- Clinical and operating risks: ELX-02 remains the only clinical-stage candidate; trial outcomes, patient recruitment, regulatory approval, manufacturing, and additional financing are uncertain. The company reported no material pending legal proceedings and said disclosure controls were effective.
Important facts for investors to verify
- Whether the company obtained funding sufficient to address the disclosed going-concern shortfall and maintain compliance with Hercules’ cash covenant.
- Alport Phase 2 enrollment, safety and efficacy data, timing of results, and whether the planned pivotal-trial decision is supported by results.
- Availability and terms of further CFF or other funding for inhaled ELX-02 and ZKN-013 development.
- Debt amortization, interest costs, any loan-tranche availability, and the effects of the CFF advances and related repayment or royalty provisions.
- Nasdaq listing compliance status and the outcome and effects of any reverse split, including potential dilution and liquidity consequences.